The Tshilo Dikotla Study: Metabolic Outcomes of Children HIV/ARV-Exposed Uninfected in Botswana

Project: Research project

Project Details

Description

Expanding use of combination antiretroviral therapy (cART) for the prevention of mother-to-child transmission (PMTCT) of HIV has dramatically decreased vertical transmission rates to <2%. The overwhelming success of PMTCT has resulted in a diminishing population of children born with perinatally acquired HIV infection on the one hand, and a mounting number of HIV-exposed uninfected (HEU) children on the other hand. Currently an estimated 20% or more of all infants born in sub-Saharan Africa are born HEU. In utero HIV/antiretroviral (ARV) and postnatal ARV treatment are known to perturb energy metabolism and could have permanent effects on the future metabolic health of HEU infants, including the development of insulin resistance. Early maladaptive changes in mitochondrial function and intermediary metabolism in HEU children exposed to ARVs may be mediated in the intrauterine environment through changes in fetal metabolic programming, and thus, may impact metabolic outcomes in these children. Through our work, we have demonstrated that exposure to specific in utero and neonatal ARVs may affect insulin sensitivity and fuel substrate utilization more than other ARVs in HEU infants early in life. Long-term and mechanistic evidence is scarce, however, in this population, particularly in sub-Saharan Africa. This study investigates the impact of in utero and postnatal HIV/ARV exposure on the metabolic health of HEU infants/children. First, we will assess whether in utero and neonatal HIV/ARV exposure is associated with changes in insulin sensitivity in HEU children from birth to 3 years of life using HIV-unexposed uninfected (HUU) infants as a comparator group. In addition, we will evaluate whether specific neonatal ARV prophylaxis regimens differ in metabolic effects amongst HEU children. Second, we will use targeted metabolomics to evaluate whether specific intermediary metabolites (short chain acylcarnitines and branched-chain amino acids) reflect or contribute to chang
StatusFinished
Effective start/end date12/1/193/31/22

Funding

  • Ann & Robert H. Lurie Children's Hospital of Chicago (901539-NU // 5R01DK109881-05)
  • National Institute of Diabetes and Digestive and Kidney Diseases (901539-NU // 5R01DK109881-05)

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.